TICKERNERD
Menu
CADLCADLHealthcare · Biotechnology

CADL Stock Forecast: Candel Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$8.30
−4.05% on the day

The 10 Wall Street analysts covering Candel Therapeutics, Inc. hold a median 12-month price target of $23 — +177.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$635.1M
Ticker Nerd rank
45/ 100
Median analyst target
$23
Analysts covering
10
Revenue$0.0
Operating income−$26.7M
Net income−$38.9M
Free cash flow−$17.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.4%
1M
−20.5%
YTD
+46.9%
1Y
+48.7%
From 52W high
−39.6%
From 52W low
+87.8%
$4
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CADL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Candel Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
45/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
77
Value
76
Accruals
72
Quality
65
Size
50
Volatility
46
Revisions
37
Growth
21
Issuance
7

Momentum (77): The shares have been drifting up relative to others.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CADL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CADL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26CADLHigh $29Median $23Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $15Median $23High $29

The green dot is the last close — the median target sits +177.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Oct 2026JefferiesInitiatesBuy$25
21 Sept 2026B of A SecuritiesUpgradeBuy$12 → $18
21 Sept 2026B of A SecuritiesUpgradeBuy—
14 Aug 2026B of A SecuritiesMaintainsNeutral$9.00 → $12
14 Aug 2026B of A SecuritiesMaintainsNeutral—
13 Aug 2026HC Wainwright & Co.ReiteratesBuy$23
13 Aug 2026HC Wainwright & Co.ReiteratesBuy—
13 July 2026StifelInitiatesBuy$22
13 July 2026StifelInitiatesBuy—
20 Apr 2026Cantor FitzgeraldInitiatesOverweight—
18 Mar 2026CitigroupMaintainsBuy—
13 Mar 2026Canaccord GenuityMaintainsBuy—
13 Mar 2026CitigroupMaintainsBuy—
8 Dec 2025Stephens & Co.ReiteratesOverweight—
21 Nov 2025Freedom BrokerMaintainsBuy—
14 Nov 2025CitigroupMaintainsBuy—
28 Oct 2025Stephens & Co.InitiatesOverweight—
21 Oct 2025LifeSci CapitalInitiatesOutperform—
29 Sept 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025B of A SecuritiesDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CADL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CADL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Candel Therapeutics, Inc. returned +48.7% against +12.4% for the S&P 500, dividends included.

CADL vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26CADLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CADL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Candel Therapeutics, Inc. (CADL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.6×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
5.0×

Cheaper than 19% of US stocks

EV / EBITDA
−7.2×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−81.8%

Higher than 15% of US stocks

Return on assets
−28.6%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Candel Therapeutics, Inc. (CADL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Candel Therapeutics, Inc. has a market value of $635.1M and an enterprise value of $509.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$88.5M.

  • Diluted earnings per share, trailing twelve months: $−1.41.

  • Free cash flow in the twelve months to 30 June 2026: −$57.3M.

  • Shares outstanding: 76.1M.

  • Trailing P/E: −11.6×; forward P/E: −13.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Candel Therapeutics, Inc. employs 55 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

CADL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CADLCandel Therapeutics, Inc.$635.1M45
OLMAOlema Pharmaceuticals, Inc.$610.1M28
ZVRAZevra Therapeutics, Inc.$603.6M96
BCAXBicara Therapeutics, Inc.$597.7M36
LXRXLexicon Pharmaceuticals, Inc.$631.8M65
CLYMClimb Bio, Inc.$586.9M55
AURAAura Biosciences, Inc.$634.8M46

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Candel Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CADL news & analysis

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

GlobeNewsWire · 29 Oct 2026positive

Candel Therapeutics said a late-breaking abstract from its phase 2 PrTK05 trial of aglatimagene besadenovec in localized prostate cancer was accepted for poster presentation at the SITC 2026 Annual Meeting, scheduled for November 4–8 in Phoenix.

Why it matters — The presentation will feature trial data on a Candel candidate being evaluated in localized prostate cancer.

Candel Therapeutics to Present at November Investor Conferences

GlobeNewsWire · 27 Oct 2026neutral

Candel Therapeutics announced that CEO Paul Peter Tak will take part in analyst-led fireside discussions and one-on-one meetings at investor conferences in November 2026.

Why it matters — The events provide opportunities for investors to hear from Candel's CEO and meet with the company.

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

GlobeNewsWire · 22 Oct 2026neutral

Candel Therapeutics appointed Maria Ostrovsky as General Counsel, effective November 3, 2026. She will oversee legal and compliance functions, including corporate governance, and report to the company’s CEO.

Why it matters — The appointment adds an executive with 20 years of legal experience, mostly in life sciences, to lead Candel’s legal and compliance work.

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

GlobeNewsWire · 2 Oct 2026positive

Candel Therapeutics announced it will present data from its aglatimagene besadenovec program in non-small cell lung cancer and clinical and mechanistic findings from its phase 1b trial of linoserpaturev in recurrent glioblastoma at the Society for Immunotherapy of Cancer's 41st Annual Meeting, held November 4-8, 2026 in Phoenix, Arizona.

Why it matters — The accepted poster presentations give Candel an opportunity to highlight clinical progress on two of its key immunotherapy programs before an oncology audience.

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 1 Oct 2026neutral

Candel Therapeutics announced that on September 30, 2026, its Compensation Committee granted inducement stock options to four new employees to purchase an aggregate of 85,900 shares of common stock at an exercise price of $10.44 per share. The grants were made under Nasdaq Listing Rule 5635(c)(4) as inducement awards.

Why it matters — CADL watchers should note the hiring of new employees and the related equity incentive grants, which reflect ongoing company operations and headcount expansion.

FAQ

Frequently asked questions about CADL stock

What is the CADL stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Candel Therapeutics, Inc. have a median 12-month price target of $23, with estimates ranging from $15 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CADL stock a buy right now?

Of the 10 analysts covering Candel Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Candel Therapeutics, Inc. 45 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CADL?

As at 31 Oct 2026, Candel Therapeutics, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (77 of 100).

Will CADL stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +177.1% from the last close, and Ticker Nerd's factor model ranks Candel Therapeutics, Inc. 45 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CADL stock forecast for 2030?

No analyst covering Candel Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CADL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $29 over the next 12 months.

How has CADL stock performed over the past year?

Candel Therapeutics, Inc. returned +48.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Candel Therapeutics, Inc. do?

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer.

What is the latest news on CADL?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer". Candel Therapeutics said a late-breaking abstract from its phase 2 PrTK05 trial of aglatimagene besadenovec in localized prostate cancer was accepted for poster presentation at the SITC 2026 Annual Meeting, scheduled for November 4–8 in Phoenix.

Company

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors. Its current pipeline includes CAN-2409, an adenovirus-based program being evaluated in cancers such as prostate, non-small cell lung, and pancreatic cancer, as well as CAN-3110, a herpes simplex virus-based candidate for recurrent high-grade glioma. The company also develops the enLIGHTEN Discovery Platform, which is used to identify and advance new viral immunotherapy candidates. Headquartered in Needham, Massachusetts, Candel Therapeutics plays a specialized role in oncology by combining viral engineering with immunology to support the development of targeted cancer treatments.

CEO Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. · 55 employees · United States · https://www.candeltx.com